Corcept Therapeutics Incorporated (CORT)
-NasdaqCM | Prev Close: | 1.76 |
|---|
| Open: | N/A |
|---|
| Bid: | 1.35 x 100 |
|---|
| Ask: | 1.82 x 800 |
|---|
| 1y Target Est: | 2.80 |
|---|
| Beta: | 1.3 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 1.27 - 4.55 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 180,079 |
|---|
| Market Cap: | 175.67M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.40 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- CORCEPT THERAPEUTICS INC FinancialsEDGAR Online Financials(Tue, May 14)
- CORCEPT THERAPEUTICS INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 8)
- Wider-than-Expected Loss at CorceptZacks(Tue, May 7)
- Corcept Therapeutics slips following downgradeAP(Mon, May 6)
- Corcept Therapeutics' CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Thu, May 2)
- Corcept Therapeutics Announces First Quarter 2013 Financial ResultsMarketwired(Thu, May 2)
- CORCEPT THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial ConditionEDGAR Online(Thu, May 2)
- Q1 2013 Corcept Therapeutics Inc Earnings Release - Time Not SuppliedCCBN(Thu, May 2)
- Corcept Therapeutics to Announce First Quarter 2013 Financial Results and Host Conference CallMarketwired(Fri, Apr 26)
- 2 High Risk Biotech Stocks Under $2 That Could Yield A High Rewardat Seeking Alpha(Wed, Apr 17)
- Opko Health CEO Buys More Than 32K Shares and 4 Insider Trades to Noteat Wall St. Cheat Sheet(Mon, Mar 18)
- CORCEPT THERAPEUTICS INC Files SEC form 10-K, Annual ReportEDGAR Online(Fri, Mar 15)
- Corcept's Loss Narrows in 4QZacks(Thu, Mar 14)
- New Star Analyst Rankings for Corcept Therapeutics IncorporatStarMine(Sat, Mar 9)
- CORCEPT THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial ConditionEDGAR Online(Fri, Mar 8)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 34.97 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.41 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.11 |
|---|
| Mean Recommendation*: | 2.3 |
|---|
| PEG Ratio (5 yr expected): | -0.14 |
|---|
Business Summary
Corcept Therapeutics Incorporated, a pharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders in the United States.
View More 
0.12%